Live Breaking News & Updates on Product Evaluation Team At Samsung Bioepis

Samsung Bioepis, Samsung Group’s biosimilar arm, announced Friday that the company had started a phase 3 clinical study for SB27, a Keytruda biosimilar. Keytruda is an immuno-oncology drug developed by MSD, a US multinational pharmaceutical company. Indications for the drug include non-small cell lung cancer (NSCLC), melanoma and neck cancer. According to MSD's earnings release, global sales of Keytruda in. ....

South Korea , Samsung Bioepis , Samsung Bioepi , Samsung Group , Product Evaluation Team At Samsung Bioepis , Hong Il Sun , Product Evaluation Team ,